Remove Ethics Remove Government Remove Healthcare Remove Leads
article thumbnail

The Ethical Challenges for Pharmaceutical Marketers in Using AI to Write Marketing Copy or Creative

Pharma Marketing Network

While AI can be a powerful tool for creating effective marketing campaigns, it also poses significant ethical challenges. One of the main ethical concerns with using AI in pharmaceutical marketing is the potential for the technology to perpetuate biases and discrimination. “The ethics of artificial intelligence.”

Ethics 52
article thumbnail

How do Healthcare AI Developers (and Buyers) Stay Ahead of the Regulatory Curve?

Nixon Gwilt Law

That said, the flurry of regulatory policymaking and legislation, congressional hearings and inquiries, and industry stakeholder organization around the development and deployment of healthcare AI portends major developments in the coming years. HIPAA is the pantheon of healthcare data privacy regulation in the U.S. HIPAA What is it?

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Data integrity considerations in Pharma and Life Sciences

European Pharmaceutical Review

Life science companies are increasingly using advanced technologies like artificial intelligence (AI), machine learning (ML) and blockchain to improve data quality and integrity by detecting anomalies in data and establishing tamper-proof audit trails for all data-related activities Data governance.

article thumbnail

The Future of Medical Sales Careers: Trends, Challenges, and Opportunities

Rep-Lite

Technological Advancements in Healthcare Sales Technological advancements have been reshaping the landscape of healthcare sales, bringing forth a new era of innovation and efficiency. The rise of telehealth is altering the way healthcare is delivered, and medical sales are following suit.

article thumbnail

Why Is FDA Issuing Fewer Marketing Violation Letters?

Pharma Marketing Network

As new healthcare challenges arise and the pharmaceutical landscape evolves, the FDA may be allocating its resources to focus on other pressing issues, such as drug approvals, monitoring emerging health threats, and enhancing drug safety. The post Why Is FDA Issuing Fewer Marketing Violation Letters?

article thumbnail

Nixon Gwilt Law Expands Corporate, M&A, and Venture Capital Capabilities with Four New Attorneys

Nixon Gwilt Law

Nixon Gwilt Law (NGL) is excited to announce a significant expansion of our core capabilities through the addition of four attorneys with expertise in healthcare mergers and acquisitions , fundraising and venture capital , and corporate/business counsel. William added, “NGL is leading the way in serving healthcare innovators.

article thumbnail

2022 Trends and Opportunities for Healthcare and Life Sciences Businesses and Investors

Nixon Gwilt Law

What can Healthcare and Life Sciences businesses and investors anticipate for the healthcare industry in 2022? We asked our team five direct questions about innovations in healthcare, life sciences, and digital health in the coming year: What healthcare trends or opportunities are you most excited about?